Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Innovative Pharmaceutical Biotech ( (HK:0399) ).
Starcoin Group Limited has announced a further extension of the long stop dates for its subscription agreements with Zhang Biaobing and Chen Jing, involving a total of 90,000,000 shares. The extension, now set to 27 October 2025, allows additional time to fulfill the conditions precedent, maintaining the terms and conditions of the original agreements. This move signifies the company’s ongoing efforts to secure necessary investments and reflects its strategic positioning in the biotech market.
More about Innovative Pharmaceutical Biotech
Starcoin Group Limited, formerly known as Innovative Pharmaceutical Biotech Limited, operates in the biotechnology industry. The company is involved in the development and commercialization of pharmaceutical products, focusing on innovative biotech solutions.
Average Trading Volume: 25,591,054
Technical Sentiment Signal: Buy
Current Market Cap: HK$803.5M
Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.